Ashley Tyce, APRN
Family · Leesburg, FLNPI 1558073924
Payments from drug & device makers
Across 303 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$814
- AstraZeneca$620
- Lilly USA, LLC$423
- Sumitomo Pharma America, Inc.$368
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$303
- Pfizer$277
- plus $4K from 30 others
What the payments were for
- Food & beverage$6,29699%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $814 |
| AstraZeneca | 30 | $620 |
| Lilly USA, LLC | 24 | $423 |
| Sumitomo Pharma America, Inc. | 18 | $368 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $303 |
| Pfizer | 15 | $277 |
| Medtronic | 2 | $270 |
| Otsuka America Pharmaceutical, Inc. | 13 | $241 |
| Eisai Inc. | 9 | $237 |
| Esperion Therapeutics, Inc. | 20 | $230 |
| Novo Nordisk | 12 | $215 |
| Boston Scientific | 2 | $203 |
| Merck | 10 | $191 |
| Amgen | 9 | $166 |
| Bayer | 7 | $165 |
| Viatris Specialty LLC | 8 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $150 |
| GSK | 7 | $141 |
| Novartis | 5 | $103 |
| Kowa Pharmaceuticals America, Inc. | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Impel Pharmaceuticals LLC | 3 | $89 |
| Astellas Pharma US Inc | 2 | $88 |
| Axsome Therapeutics, Inc. | 3 | $80 |
| Johnson & Johnson | 4 | $78 |
| Boehringer Ingelheim | 3 | $74 |
| Shield Therapeutics Inc | 4 | $74 |
| Evoke Pharma, Inc. | 4 | $69 |
| Exact Sciences | 3 | $68 |
| Paratek Pharmaceuticals, Inc. | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Lundbeck LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$168
- Protege RX$153
- SYMPLICITY G3$117
- CAPLYTA$103
How this compares
$6,369 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $51,845 |
| EliquisApixaban | 18 | $22,325 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,707 |
| Repatha SureclickEvolocumab | 11 | $10,494 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $9,242 |
| Rosuvastatin Calcium | 75 | $1,089 |
| Levothyroxine Sodium | 74 | $891 |
| Fluticasone Propionate | 62 | $859 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $747 |
| Gabapentin | 38 | $674 |
| Atorvastatin Calcium | 69 | $650 |
| Cyclobenzaprine Hcl | 46 | $591 |
| Pantoprazole Sodium | 28 | $572 |
| Ezetimibe | 15 | $571 |
| Montelukast Sodium | 31 | $522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $423 | $51,84547 claims |
| PfizerEliquis | $277 | $22,32518 claims |
| GSKTrelegy Ellipta | $141 | $10,70712 claims |
| Esperion Therapeutics, Inc.Nexlizet | $230 | $9,24215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Leesburg
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.